UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 25

Sortiert nach

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

Journal of clinical oncology, 2013-07, Vol.31 (19), p.2388-2395

2013

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma

Journal of clinical oncology, 2012-11, Vol.30 (31), p.3810-3818

2012

Link zum Volltext

Verfügbarkeit prüfen

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

Journal of clinical oncology, 2013-07, Vol.31 (19), p.2413-2420

2013

Link zum Volltext

Verfügbarkeit prüfen

Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment

European journal of cancer (1990), 2016-03, Vol.56, p.101-106

2016

Link zum Volltext

Verfügbarkeit prüfen

Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study)

European journal of cancer (1990), 2009-12, Vol.45 (18), p.3189-3197

2009

Link zum Volltext

Verfügbarkeit prüfen

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

The lancet oncology, 2018-07, Vol.19 (7), p.916-929

2018

Link zum Volltext

Verfügbarkeit prüfen

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience

Journal of clinical oncology, 2006-05, Vol.24 (13), p.e20-e22

2006

Link zum Volltext

Verfügbarkeit prüfen

Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands

Melanoma research, 2021-06, Vol.31 (3), p.249

2021

Link zum Volltext

Verfügbarkeit prüfen

Pimasertib‐associated ophthalmological adverse events

Acta ophthalmologica (Oxford, England), 2018-11, Vol.96 (7), p.712-718

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma

International journal of cancer, 2005-11, Vol.117 (4), p.596-604

2005

Link zum Volltext

Verfügbarkeit prüfen

Thalidomide in solid tumours: the resurrection of an old drug

European journal of cancer (1990), 2004-11, Vol.40 (16), p.2377-2382

2004

Link zum Volltext

Verfügbarkeit prüfen

Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)

Cancer Immunology, Immunotherapy, 2013-07, Vol.62 (7), p.1223-1233

2013

Link zum Volltext

Verfügbarkeit prüfen

Repeated Administrations of Interleukin (IL)-12 Are Associated with Persistently Elevated Plasma Levels of IL-10 and Declining IFN-γ, Tumor Necrosis Factor-α, IL-6, and IL-8 Responses

Clinical cancer research, 2003-01, Vol.9 (1), p.76-83

2003

Link zum Volltext

Verfügbarkeit prüfen

Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-α therapy

Amino acids, 2009-10, Vol.37 (4), p.703-708

2009

Link zum Volltext

Verfügbarkeit prüfen

Interferon-α Influences Tryptophan Metabolism without Inducing Psychiatric Side Effects

Neuropsychobiology, 2007-01, Vol.55 (3-4), p.225-231

2007

Link zum Volltext

Verfügbarkeit prüfen

Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients

Psychiatry research, 2003-07, Vol.119 (1), p.125-132

2003

Link zum Volltext

Verfügbarkeit prüfen

Pegylated interferon-α2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations

Anti-cancer drugs, 2004-07, Vol.15 (6), p.587-591

2004

Link zum Volltext

Verfügbarkeit prüfen

Interleukin 12 induces activation of fibrinolysis and coagulation in humans

British journal of haematology, 2001-02, Vol.112 (2), p.499-505

2001

Link zum Volltext

Verfügbarkeit prüfen

Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients

Progress in neuro-psychopharmacology & biological psychiatry, 2005, Vol.29 (1), p.109-114

2005

Link zum Volltext

Verfügbarkeit prüfen

Adverse Effect on Bone Marrow Protection of Prechemotherapy Granulocyte Colony-Stimulating Factor Support

JNCI : Journal of the National Cancer Institute, 1996-10, Vol.88 (19), p.1393-1398

1996

Link zum Volltext

Verfügbarkeit prüfen

The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon α and lymphokine-activated killer cells

Cancer Immunology, Immunotherapy, 1999-09, Vol.48 (6), p.331-335

1999

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4603: Targeted treatment of metastatic melanoma through interference with Pin1-FOXM1 signaling

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.4603-4603

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 25

Suche als RSS-Feed

Aktive Filter

ThemaDose-Response Relationship, Drug

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(22)
Life Sciences & Biomedicine
(22)
Science & Technology
(22)
Female
(18)
Middle Aged
(18)
Adult
(17)
Aged
(17)
Male
(17)
Oncology
(16)
Melanoma - Drug Therapy
(13)
Biological And Medical Sciences
(11)
Medical Sciences
(11)
Skin Neoplasms - Drug Therapy
(10)
Pharmacology. Drug Treatments
(8)
Tumors
(8)
Interferon-Alpha - Therapeutic Use
(7)
Melanoma
(7)
Treatment Outcome
(6)
Depression
(5)
Recombinant Proteins - Therapeutic Use
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma

Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

Macrocytosis as a potential parameter associated with survival after tyrosine kinase inhibitor treatment

Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands

Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study)

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience

Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands

Pimasertib‐associated ophthalmological adverse events

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma

Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry

Thalidomide in solid tumours: the resurrection of an old drug

Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study)

Repeated Administrations of Interleukin (IL)-12 Are Associated with Persistently Elevated Plasma Levels of IL-10 and Declining IFN-γ, Tumor Necrosis Factor-α, IL-6, and IL-8 Responses

Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-α therapy

Interferon-α Influences Tryptophan Metabolism without Inducing Psychiatric Side Effects

Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients

Pegylated interferon-α2b treatment in melanoma patients: influence on amino acids, 5-hydroxyindolacetic acid and pteridine plasma concentrations

Interleukin 12 induces activation of fibrinolysis and coagulation in humans

Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients

Adverse Effect on Bone Marrow Protection of Prechemotherapy Granulocyte Colony-Stimulating Factor Support

The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon α and lymphokine-activated killer cells

Abstract 4603: Targeted treatment of metastatic melanoma through interference with Pin1-FOXM1 signaling

Aktive Filter

Suchergebnisse filtern